Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-22

Study Completion Date

2024-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase Ib Study of NVX-508 in Sickle Cell Disease

NCT03013426

Sickle Cell Disease

WITHDRAWN PHASE1

AB1 in Adult Patients with Sickle Cell Disease (SCD)

NCT05261711

Sickle Cell Disease

TERMINATED PHASE1/PHASE2

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

NCT01783691

Sickle Cell Disease

COMPLETED PHASE1

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324

Sickle Cell Disease

TERMINATED PHASE1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265

Hematologic Diseases Anaemia, Sickle Cell

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease (SCD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALXN1820 300 mg once weekly

Participants will receive 300 milligrams (mg) once weekly (QW).

Group Type EXPERIMENTAL

ALXN1820

Intervention Type DRUG

ALXN1820 will be administered subcutaneously.

ALXN1820 600 mg once every 4 weeks

Participants will receive 600 mg once every 4 weeks (Q4W).

Group Type EXPERIMENTAL

ALXN1820

Intervention Type DRUG

ALXN1820 will be administered subcutaneously.

ALXN1820 300 mg once every 2 weeks (Optional cohort)

Participants will receive 300 mg once every 2 weeks (Q2W).

Group Type EXPERIMENTAL

ALXN1820

Intervention Type DRUG

ALXN1820 will be administered subcutaneously.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALXN1820

ALXN1820 will be administered subcutaneously.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of SCD (HbSS, or HbSβ0-thalassemia).
* Body weight ≥ 40 kg (inclusive) at Screening.
* Must follow protocol-specified contraception guidance while on treatment and for up to 6 months after last dose.
* Hemoglobin between 5.5 and 10 g/dL at Screening
* Have had 1 to 10 VOCs in the past 12 months.
* Patients receiving hydroxyurea must have been on a stable dose for ≥ 3 months prior to providing informed consent, with no anticipated need for dose adjustment during the study.
* Patients will be vaccinated with MCV4 and serogroup B meningococcal vaccinations at least 14 days before dosing, if not already vaccinated within 3 years before the first dose.
* Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae vaccination are up to date according to current national/local vaccination guidelines for patients with SCD.

Exclusion Criteria

* Planned initiation, termination, or dose alteration of hydroxyurea during the study.
* Receiving Voxelotor (OXBRYTA) or crizanlizumab (ADAKVEO) within 60 days of providing informed consent.
* Receiving treatment with recombinant human erythropoetins (eg, epoetin alfa).
* Treated with complement inhibitors within 6 months prior to the first dose.
* Patients who are on chronic transfusion or receive a transfusion within 60 days of first dose.
* Any significant disease or disorder which, in the opinion of the Investigator, may put the participant at risk.
* Hepatitis B (positive hepatitis surface antigen \[HBsAg\] or positive core antibody (anti-HBc) with negative surface antibody \[anti-HBs\]) or hepatitis C viral infection (hepatitis C virus \[HCV\] antibody positive, except for patients with documented successful treatment and documented sustained virologic response) at Screening.
* Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing.
* Participation (ie, last protocol-required study visit) in a clinical study within 90 days or 5 half-lives of the investigational agent, whichever is longer, before initiation of dosing on Day 1.
* Participation in more than 1 clinical study of a monoclonal antibody (mAb), or participation in a clinical study of a mAb within the 6 months or 5 half-lives of the mAb, whichever is longer, prior to Screening, during which the participant was exposed to the active study drug.
* Severe renal impairment (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m2 ) or on chronic dialysis.
* History of allergy or hypersensitivity to excipients of ALXN1820 (eg, polysorbate 80).
* History of complement deficiency.
* History of N meningitidis, S pneumoniae, or H influenzae infection.
* History of malignancy with the exception of a nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence within 5 years.
* Participants who are pregnant or breastfeeding.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No